Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 321

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 321
---
31, 2024— — Additional paid-in capital282,675,249 265,650,362 Accumulated deficit(253,775,199)(224,295,186)Total stockholders' equity28,936,037 41,386,226 Total liabilities and stockholders' equity$40,056,468 $52,714,413 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

7

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Operating expensesResearch and development$10,454,160 $10,651,958 $21,925,852 $21,854,372 General and administrative4,296,417 4,254,473 8,302,059 8,370,493 Amortization of intangible asset7,317 7,317 14,633 14,633 Total operating expenses14,757,894 14,913,748 30,242,544 30,239,498 Loss from operations(14,757,894)(14,913,748)(30,242,544)(30,239,498)Other income (expense)Interest income324,013 826,104 762,532 1,630,988 Other income, net— 7,717 — 220,754 Net loss$(14,433,881)$(14,079,927)$(29,480,012)$(28,387,756)Net loss per share attributable to common stockholders, basic and diluted$(0.40)$(0.47)$(0.82)$(0.96)Weighted-average common shares outstanding, basic and diluted35,985,87829,653,35535,759,02629,511,856Other comprehensive loss:Unrealized loss from marketable securities— 1,084 — 778 Comprehensive Loss$(14,433,881)$(14,078,843)$(29,480,012)$(28,386,978)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

8

Table of Contents

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF